Evidence map›Paper›PMID 38520597›Full record

ArticleBreast cancer research and treatment2024

Germline pathogenic variants associated with triple-negative breast cancer in US Hispanic and Guatemalan women using hospital and community-based recruitment strategies.

Jesica M Godinez Paredes, Isabel Rodriguez, Megan Ren, Anali Orozco, Jeremy Ortiz, Anaseidy Albanez, Catherine Jones, Zeina Nahleh, Lilian Barreda, Lisa Garland and 8 more

Open access · hybridAbstract read
In one paragraph

Article in Breast cancer research and treatment, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
2.2field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 4 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 7 institutions in 2 countries.

Jesica M Godinez ParedesDivision of Cancer Epidemiology and Genetics, National Cancer Institute, NIH, Gaithersburg, MD, USA.
Isabel RodriguezDivision of Cancer Epidemiology and Genetics, National Cancer Institute, NIH, Gaithersburg, MD, USA.
Megan RenDivision of Cancer Epidemiology and Genetics, National Cancer Institute, NIH, Gaithersburg, MD, USA.
Anali OrozcoInstituto Cancerologia, Guatemala City, Guatemala.
Jeremy OrtizInstituto Cancerologia, Guatemala City, Guatemala.
Anaseidy AlbanezInstituto Cancerologia, Guatemala City, Guatemala.
Catherine JonesTexas Tech University Health Sciences Center, Lubbock, TX, USA.
Zeina NahlehCleveland Clinic Florida, Weston, FL, USA.
Lilian BarredaHospital General San Juan de Dios, Guatemala City, Guatemala.
Lisa GarlandCancer Genetics Research Laboratory, Division of Cancer Epidemiology and Genetics, Frederick National Laboratory for Cancer Research, Gaithersburg, MD, USA.
Edmundo Torres-GonzalezDivision of Cancer Epidemiology and Genetics, National Cancer Institute, NIH, Gaithersburg, MD, USA.
Dongjing WuCancer Genetics Research Laboratory, Division of Cancer Epidemiology and Genetics, Frederick National Laboratory for Cancer Research, Gaithersburg, MD, USA.
Wen LuoCancer Genetics Research Laboratory, Division of Cancer Epidemiology and Genetics, Frederick National Laboratory for Cancer Research, Gaithersburg, MD, USA.
Jia LiuCancer Genetics Research Laboratory, Division of Cancer Epidemiology and Genetics, Frederick National Laboratory for Cancer Research, Gaithersburg, MD, USA.
Victor ArguetaHospital General San Juan de Dios, Guatemala City, Guatemala.
Roberto OrozcoHospital General San Juan de Dios, Guatemala City, Guatemala.
Eduardo GharzouziIntegra Cancer Center, Guatemala City, Guatemala.
Michael DeanDivision of Cancer Epidemiology and Genetics, National Cancer Institute, NIH, Gaithersburg, MD, USA. deanm@mail.nih.gov.ORCID http://orcid.org/0000-0003-2234-0631
National Cancer Institute · USFrederick National Laboratory for Cancer Research · USHospital General San Juan de Dios · GTLiga Nacional Contra el Cáncer · GTCentro de Epilepsia y Neurocirugía Funcional · GTCleveland Clinic Florida · USTexas Tech University · US

Funding

Laboratory of Translational GenomicsZIACP010201 · NCI · DIVISION OF CANCER EPIDEMIOLOGY AND GENETICS · PI PROKUNINA-OLSSON, LIUDMILA · 2010 to 2025
$91.2M
Division of Cancer Epidemiology and Genetics, National Cancer Institute ZIACP010201Intramural NIH HHS ZIA CP010201
6 · The paper itself

Abstract

purposeRecruit and sequence breast cancer subjects in Guatemalan and US Hispanic populations. Identify optimum strategies to recruit Latin American and Hispanic women into genetic studies of breast cancer.

methodsWe used targeted gene sequencing to identify pathogenic variants in 19 familial breast cancer susceptibility genes in DNA from unselected Hispanic breast cancer cases in the US and Guatemala. Recruitment across the US was achieved through community-based strategies. In addition, we obtained patients receiving cancer treatment at major hospitals in Texas and Guatemala.

resultsWe recruited 287 Hispanic US women, 38 (13%) from community-based and 249 (87%) from hospital-based strategies. In addition, we ascertained 801 Guatemalan women using hospital-based recruitment. In our experience, a hospital-based approach was more efficient than community-based recruitment. In this study, we sequenced 103 US and 137 Guatemalan women and found 11 and 10 pathogenic variants, respectively. The most frequently mutated genes were BRCA1, BRCA2, CHEK2, and ATM. In addition, an analysis of 287 US Hispanic patients with pathology reports showed a significantly higher percentage of triple-negative disease in patients with pathogenic variants (41% vs. 15%). Finally, an analysis of mammography usage in 801 Guatemalan patients found reduced screening in women with a lower socioeconomic status (p < 0.001).

conclusionGuatemalan and US Hispanic women have rates of hereditary breast cancer pathogenic variants similar to other populations and are more likely to have early age at diagnosis, a family history, and a more aggressive disease. Patient recruitment was higher using hospital-based versus community enrollment. This data supports genetic testing in breast cancer patients to reduce breast cancer mortality in Hispanic women.

Indexed as

Genetic Predisposition to DiseaseGerm-Line MutationHispanic or LatinoTriple Negative Breast NeoplasmsAdultAgedFemaleGuatemalaHumansMiddle AgedPatient SelectionTexasUnited StatesBreast cancerEarly ageGlobal healthHealth disparitiesHereditaryLatin AmericaMammographyPathogenic variantsSocioeconomicTriple-negative

Identifiers

PMID38520597
PMCPMC11101360
OpenAlexW4393118938

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.